Patents by Inventor Cunyu Zhang

Cunyu Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250136722
    Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.
    Type: Application
    Filed: August 12, 2022
    Publication date: May 1, 2025
    Inventors: Peiling CHEN, Michael Gerard DARCY, Jason W. DODSON, Beth A. KNAPP-REED, Craig LEACH, Yuehu LI, Andrew Peter MARCUS, Joseph Paul MARINO, Jeffrey Alan OPLINGER, James P. PHELAN, Matthew Robert SENDER, Brandon TURUNEN, Guosen YE, Cunyu ZHANG, Jae U. JEONG
  • Patent number: 12252471
    Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.
    Type: Grant
    Filed: October 20, 2023
    Date of Patent: March 18, 2025
    Assignee: DERMAVANT SCIENCES GMBH
    Inventors: Channa K. Jayawickreme, Susan H. Smith, Cunyu Zhang, William Zuercher
  • Publication number: 20250057958
    Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.
    Type: Application
    Filed: August 13, 2024
    Publication date: February 20, 2025
    Inventors: Peiling Chen, Michael Gerard Darcy, Jason W. Dodson, Beth Anne Knapp-Reed, Joseph Paul Marino, JR., Jeffrey Alan Oplinger, Matthew Robert Sender, Brandon James Turunen, Guosen Ye, Cunyu Zhang
  • Publication number: 20250051479
    Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, or autoimmune diseases.
    Type: Application
    Filed: August 13, 2024
    Publication date: February 13, 2025
    Inventors: Brandon James Turunen, Cunyu Zhang
  • Publication number: 20240325392
    Abstract: The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.
    Type: Application
    Filed: February 9, 2024
    Publication date: October 3, 2024
    Inventors: Peiling CHEN, Jason W. DODSON, Beth A. KNAPP-REED, Craig LEACH, Yuehu LI, Joseph Paul MARINO, JR., Matthew Robert SENDER, Brandon TURUNEN, Guosen YE, Cunyu ZHANG
  • Publication number: 20240208910
    Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.
    Type: Application
    Filed: October 20, 2023
    Publication date: June 27, 2024
    Applicant: Dermavant Sciences GmbH
    Inventors: Channa K. JAYAWICKREME, Susan H. SMITH, Cunyu ZHANG, William ZUERCHER
  • Patent number: 11827605
    Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: November 28, 2023
    Assignee: DERMAVANT SCIENCES GMBH
    Inventors: Channa K. Jayawickreme, Susan H. Smith, Cunyu Zhang, William Zuercher
  • Publication number: 20230124135
    Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.
    Type: Application
    Filed: October 28, 2022
    Publication date: April 20, 2023
    Applicant: Dermavant Sciences GmbH
    Inventors: Channa K. JAYAWICKREME, Susan H. SMITH, Cunyu ZHANG, William ZUERCHER
  • Patent number: 11548853
    Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: January 10, 2023
    Assignee: DERMAVANT SCIENCES GMBH
    Inventors: Channa K. Jayawickreme, Susan H. Smith, Cunyu Zhang, William Zuercher
  • Publication number: 20220153703
    Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.
    Type: Application
    Filed: January 28, 2022
    Publication date: May 19, 2022
    Inventors: Channa K. JAYAWICKREME, Susan H. SMITH, Cunyu ZHANG, William ZUERCHER
  • Patent number: 11267788
    Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: March 8, 2022
    Assignee: DERMAVANT SCIENCES GMBH
    Inventors: Channa K. Jayawickreme, Susan H. Smith, Cunyu Zhang, William Zuercher
  • Publication number: 20220017468
    Abstract: The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.
    Type: Application
    Filed: May 27, 2021
    Publication date: January 20, 2022
    Inventors: Channa K. JAYAWICKREME, Susan H. SMITH, Cunyu ZHANG, William ZUERCHER
  • Publication number: 20140323487
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Patent number: 8822518
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 2, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Publication number: 20140100255
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu ZHANG, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Patent number: 8633175
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: January 21, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Publication number: 20110124559
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: August 8, 2007
    Publication date: May 26, 2011
    Applicant: Smithkline Beecham Corporation
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Publication number: 20100222345
    Abstract: This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.
    Type: Application
    Filed: August 8, 2007
    Publication date: September 2, 2010
    Inventors: Caroline Jean Diaz, Curt Dale Haffner, Jason Daniel Speake, Cunyu Zhang, Wendy Yoon Mills, Paul Kenneth Spearing, David John Cowan, Gary Martin Green
  • Publication number: 20070225287
    Abstract: Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.
    Type: Application
    Filed: February 16, 2007
    Publication date: September 27, 2007
    Inventors: Taeyoung Yoon, Ping Ge, Raymond Horvath, Stephane DeLombaert, Kevin Hodgetts, Dario Doller, Cunyu Zhang
  • Patent number: 7202250
    Abstract: Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.
    Type: Grant
    Filed: April 15, 2005
    Date of Patent: April 10, 2007
    Assignee: Neurogen Corporation
    Inventors: Taeyoung Yoon, Ping Ge, Raymond F. Horvath, StÄ—phane DeLombaert, Kevin J. Hodgetts, Dario Doller, Cunyu Zhang